Ann: Phase 1 onCARlytics Trial Doses First Intravenous Patient, page-62

The majority of announcements released over the last 2 years from Imugene during the macro meltdown have been positive, however positive does not translate to price action. There have only been 1 or two announcements that one would logically expect to move the share price in a meaningful way. The rest of the announcements are confirmatory and box ticking. These all add up of course, but by themselves are not price movers. The price movers, like the first data readout and fast track did have a meaningful impact on the price. We ran from about 5c to 15c with nearly 2 billion shares traded in the period. Every positive announcement adds buying pressure, however it still takes the big announcements to see the movement. At some point soon though, the pressure will give in, perhaps even on seemingly insignificant news and we'll be off. For now, we far as the share price goes, we should be content that we are progressing through the necessary churn. It's been ready to go at a moments notice, and the breakout from the current range only becomes all the more fragile with the passing of time.